Press Releases
Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)
Sep 30, 2026
Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab
Sep 28, 2026
Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab
Sep 21, 2026
Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center
Sep 17, 2026
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
Aug 24, 2026
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
Aug 06, 2026
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
Aug 04, 2026
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
Jul 31, 2026
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
Jul 22, 2026
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
Jun 25, 2026
Displaying 1 - 10 of 552